- |||||||||| Prolia (denosumab) / Amgen
Trial completion date, Trial primary completion date: Denosumab for Type 1 Diabetes (clinicaltrials.gov) - Aug 27, 2024
P1/2, N=45, Recruiting,
N=1000 --> 540 Trial completion date: Dec 2026 --> Apr 2026 | Trial primary completion date: Sep 2026 --> Apr 2026
- |||||||||| Polivy (polatuzumab vedotin-piiq) / Roche, Neulasta (pegfilgrastim) / Roche
Journal, Combination therapy: The Utility of Primary Prophylaxis with Pegfilgrastim in Combination with Polatuzumab Vedotin Therapy (Pubmed Central) - Aug 27, 2024
The duration of hospitalization significantly decreased in the Pola-BR group with G-CSF(11 days vs. 18 days in the group without G-CSF), suggesting that prophylaxis might contribute to this reduction. Although not statistically significant, prophylactic G-CSF administration tended to reduce the incidence of Grade 3 or higher leukopenia and neutropenia, suggesting that primary prophylactic G-CSF administration in Pola combination therapy could contribute to reduced hematologic toxicity.
- |||||||||| Neulasta (pegfilgrastim) / Roche
Journal: Approaches and Challenges in the Clinical Application of On-Body Injector(G-Lasta BodyPod) (Pubmed Central) - Aug 27, 2024
We categorized BodyPod- related issues as(1)allergic symptoms after application and Peg-G injection,( 2)malfunction or failure before initiating the Peg-G injection, or(3)malfunction or failure after initiating the Peg-G injection. In conclusion, a careful understanding of the handling and malfunction of the BodyPod is essential prior to application in clinical settings, along with patient indications and troubleshooting guidelines appropriate for each hospital.
- |||||||||| Difficult asthma: Pearls and pitfalls (Hall 303, Level 3) - Aug 27, 2024 - Abstract #MTS2024MTS_27;
Tezepelumab also treats non-Type 2 asthma but is only licensed for children aged 12 years and over...This should include determining what went wrong, and if necessary, developing a new asthma plan. An asthma attack is an acute sign of suboptimal management of a chronic disease
- |||||||||| Tavneos (avacopan) / Amgen
Journal: A case of rapid avacopan-induced liver injury in pediatric granulomatosis with polyangiitis. (Pubmed Central) - Aug 27, 2024
Discontinuation of rituximab and avacopan resulted in improved liver function; no change in the Birmingham Vasculitis Activity Score during liver function test abnormalities was observed. Avacopan-associated abnormalities in liver function tests suggest that drug-induced liver injury may occur rapidly in children, and appropriate dosing strategies should be reconsidered.
- |||||||||| Review, Journal: RNA interference therapy in cardiology: will new targets improve therapeutic goals? (Pubmed Central) - Aug 27, 2024
Zilebesiran, which targets hepatic angiotensinogen mRNA, has demonstrated a dose-related reduction in serum angiotensinogen levels, thereby lowering blood pressure in patients with systemic arterial hypertension...In the future, larger studies will provide insights into improvements in cardiovascular outcomes, long-term safety and broader applications in the general population. This review highlights the historical timeline of the development of siRNA-based drugs, their clinical indications, potential side-effects and future perspectives.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen, Actemra IV (tocilizumab) / Roche, JW Pharma, Kineret (anakinra) / SOBI
Journal, CAR T-Cell Therapy: Novel Treatment Modality for Chimeric Antigen Receptor T-cell Therapy Complications: A Case Report. (Pubmed Central) - Aug 27, 2024
Our patient presented with an extensive past medical history, including refractory B-ALL, and developed CRS and ICANS following treatment with blinatumomab CAR-T cell therapy. Early clinical detection of ICANS, monitoring using immune effector cell encephalopathy scores, following the appropriate protocol for ICANS grade, and adding anakinra (IL-1 receptor antagonist) were crucial steps in managing his condition.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Anti-RANKL Antibody For Active Charcot Foot Neuro-Osteoarthropathy in Patients with Diabetes and Chronic Kidney Disease. (Pubmed Central) - Aug 27, 2024
Chronic kidney disease (CKD) precludes bisphosphonates but anti-receptor activator of nuclear factor-B ligand (anti-RANKL) antibody, denosumab, can be contemplated in CKD...25-Hydroxyvitamin D3 >14?ng/mL was significantly associated (OR 9.5, 95% CI 1.04-87.5, P?=?.045) with remission. Anti-RANKL antibody added to SoC (TCC) induces remission of active foot CNO in greater proportions of patients with diabetes and CKD.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Review, Journal: Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies. (Pubmed Central) - Aug 27, 2024
Since the approval of the bispecific antibody blinatumomab in 2017 for the treatment of acute lymphoblastic leukemia in relapse, the development of numerous bispecific antibody constructs has dramatically expanded in hematologic malignancies...It is important to continue to investigate new designs, tumor antigen targets, and further refine where current approved bispecific antibodies fit in terms of sequencing of therapy. Hopefully, with the knowledge gained in recent years and the explosion of these therapies, patients with blood cancers will continue to benefit from these treatments for years to come.
- |||||||||| Prolia (denosumab) / Amgen
Review, Journal: Incomplete femoral neck fracture with characteristics of atypical femoral fracture: A case report and literature review. (Pubmed Central) - Aug 26, 2024
A 76-year-old woman had been treated with denosumab for five years...In a patient with long-term bisphosphonate use, complaints of hip pain could indicate the possibility of an atypical fracture. According to the existing literature, as with atypical femoral fractures, this fracture has a high risk of delayed union; therefore, temporary prosthetic replacement should be considered as a treatment option.
- |||||||||| Vyloy (zolbetuximab) / Astellas, bemarituzumab (AMG 552) / Amgen
Review, Journal: New therapeutic target molecules for gastric and gastroesophageal junction cancer. (Pubmed Central) - Aug 26, 2024
Phase III and Ib/III trials of the FGFR2-targeted antibody bemarituzumab for G/GEJ cancer overexpressing FGFR2b are ongoing based on the promising result in a phase II trial, especially in cases with an FGFR2b positivity of???10%...CLDN18.2 is expressed in some G/GEJ tumors but lacks oncogenic driver potential, and the CLDN18.2-targeted antibody zolbetuximab prolonged the survival of CLDN18.2-positive G/GEJ cancer patients in phase III trials...Similarly, targeting of nondriver molecules such as DKK1, TROP2, and CEACAM5 is under investigation in early-stage clinical trials. This shift in focus from target molecules with driver potential to markers for precise drug delivery should increase the number of possible targets in G/GEJ cancer.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Journal: Percent reduction in proptosis after teprotumumab treatment for thyroid eye disease. (Pubmed Central) - Aug 26, 2024
In this retrospective study analysing proptosis change as a percentage of pre-treatment proptosis among 119 patients, 208 (87.4%) eyes of 110 patients had proptosis reduction averaging 14.4% (range 2.2-40.5%) of their pre-treatment proptosis, or 3.3?mm (range 0.5-10.0?mm). Reporting proptosis reduction as a percentage of pre-treatment proptosis provides a better understanding of teprotumumab's clinical impact.
- |||||||||| Epogen (epoetin alfa) / Amgen, Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
P3 data, Journal: Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial. (Pubmed Central) - Aug 26, 2024
P3
Luspatercept represents a new standard of care for ESA-naive patients with transfusion-dependent, lower-risk myelodysplastic syndromes. Significantly more patients had red blood cell transfusion independence and haematological improvement with luspatercept than with epoetin alfa, with benefits observed across patient subgroups.
- |||||||||| P1 data, Journal, Checkpoint inhibition: Safety of combined ablative radiotherapy and immune checkpoint inhibitors in three phase I trials. (Pubmed Central) - Aug 24, 2024
This analysis features the largest prospectively evaluated cohort of patients treated with combination ablative SBRT and ICI to date and provides context for future trial design. We conclude that multi-site SBRT and ICI can be safely co-administered when SBRT is delivered with prioritization of normal tissue constraints.
- |||||||||| Aimovig (erenumab-aooe) / Amgen, Novartis
Retrospective data, Journal, HEOR, Real-world evidence, Real-world: Changes in Use of Migraine Medications, Healthcare Resource Utilization, and Associated Direct Costs Over 12 (Pubmed Central) - Aug 23, 2024
Most patients initiating erenumab had prior use of acute and traditional migraine-preventive therapies. The reduction in acute and traditional migraine-preventive medication use and HRU over the 12-month follow-up supports the long-term clinical benefits of erenumab in the real-world setting.
- |||||||||| Enbrel (etanercept) / Pfizer, Amgen
Clinical, Review, Journal: Perispinal etanercept stroke trial design: PESTO and beyond. (Pubmed Central) - Aug 23, 2024
RCTs failing to incorporate these elements, such as the PESTO trial, are incapable of reaching reliable conclusions regarding PSE efficacy. SF-36 has not been validated in PSE trials and is unsuitable for use as a primary outcome measure in PSE RCTs.
- |||||||||| Repatha (evolocumab) / Amgen, Astellas
Clinical, Retrospective data, Review, Journal: Strategies to Address Statin Medication Intolerance Among Patients at Risk of Cardiovascular Disease Identified Through Electronic Health Records: A Literature Review and Pooled Analysis. (Pubmed Central) - Aug 23, 2024
The overall relative risk (RR) was 0.40 (95% CI, 0.09 to 1.70) with I2 90%, and the overall odds ratio (OR) was 0.11 (95% CI, 0.01 to 1.59) with I2 94%, suggesting that the interventions work well in addressing statin intolerance. Since statin intolerance is has a vast range of effects, further research works may be done on exploring the possibility of using digital health systems to identify and provide targeted interventions to patients.
- |||||||||| Review, Journal: Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-interleukins (Pubmed Central) - Aug 23, 2024
The review then discusses anti-IL therapies, focusing primarily on ustekinumab (anti-IL-12/23), risankizumab (anti-IL-23), and mirikizumab (anti-IL-23)...The review also briefly discusses emerging therapies such as guselkumab and brazikumab...These agents may be considered first- or second-line therapies for many patients, especially those with comorbidities or safety concerns. Anti-IL therapies represent a significant advancement in IBD treatment, offering effective and relatively safe options for patients with moderate to severe disease.
- |||||||||| Review, Journal: Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti Integrins (Pubmed Central) - Aug 23, 2024
In addition, the introduction of subcutaneous vedolizumab showed similar efficacy and safety with improved patients' convenience. Other investigational anti-integrin therapies include abrilumab (anti-?4?7 IgG2), PN-943 (orally administered and gut-restricted ?4?7 antagonist peptide), AJM300 (orally active small molecule inhibitor of ?4), and ontamalimab (anti-MAdCAM-1 IgG).
- |||||||||| Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen
Journal, Metastases: Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer. (Pubmed Central) - Aug 23, 2024
Based on these results, phase III clinical trials are being conducted to investigate EGFR and KRAS G12C inhibitor combinations as a first or second-line treatment for KRAS G12C mutated advanced CRC. Furthermore, other KRAS G12C inhibitors, KRAS G12D inhibitors, and pan-RAS inhibitors are being developed, which could make more patients with advanced CRC eligible for KRAS inhibition.
- |||||||||| Doptelet (avatrombopag) / SOBI
Journal: Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report. (Pubmed Central) - Aug 23, 2024
Furthermore, other KRAS G12C inhibitors, KRAS G12D inhibitors, and pan-RAS inhibitors are being developed, which could make more patients with advanced CRC eligible for KRAS inhibition. Here, we describe treatment with avatrombopag, a thrombopoietin receptor agonist, in a pediatric patient with chronic, severe, transfusion-dependent thrombocytopenia (100
- |||||||||| Prolia (denosumab) / Amgen
Journal: Denosumab-induced Acute Generalized Exanthematous Pustulosis. (Pubmed Central) - Aug 23, 2024
Here, we describe treatment with avatrombopag, a thrombopoietin receptor agonist, in a pediatric patient with chronic, severe, transfusion-dependent thrombocytopenia (100 No abstract available
|
